Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aurinia Pharmaceuticals Inc. Director's Dealing 2021

May 13, 2021

31941_dirs_2021-05-13_9fd8f1d8-67f3-4209-9c91-f37f11258f8e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-05-11

Reporting Person: MacKay-Dunn R. Hector (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-05-11 Common Stock P 500 $11.17 Acquired 2000 Direct
2021-05-11 Common Stock P 1000 $11.14 Acquired 3000 Direct
2021-05-12 Common Stock P 1400 $11.26 Acquired 4400 Direct
2021-05-12 Common Stock P 1600 $11.275 Acquired 6000 Direct